1,720,969 research outputs found
Dalla modulazione cardiovascolare a quella metabolica: nuove prospettive terapeutiche nella prevenzione del diabete.
No full textIn termini meccanicistici l'aspetto più interessante è certamente rappresentato dalla dimostrazione che il blocco RAS ottenuto attraverso la riduzione dei livelli di angiotensina II od il blocco recettoriale AT1 è in grado di rimuovere gli effetti negativi nei confronti del recettore per la insulina limitando la resistenza insulinica responsabile dello sviluppo di iperglicemia e, potenzialmente, di diabete
Quality of life of children with familial hyperlipidemias after quantitative or qualitative dietary restriction
No full textBlood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice
No full textThe aim of this study is to assess the blood pressure (BP) and metabolic effects of lercanidipine when combined with other classes of first-line antihypertensive drugs in day-to-day clinical practice. For this study, we consecutively enrolled 162 patients with uncomplicated primary hypertension, who are partial responders to the treatment with lercanidipine over a period of 24 months. Patients were then allocated to the combination of lercanidipine (10-20 mg/day) with β-blockers, diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-ll receptor blockers according to compelling indications (if any) and/or suggestions of European Society of Hypertension-European Society of Cardiology (ESH-ESC) guidelines. All the enrolled patients completed the study and no adverse drug reaction was registered during the research period. The association of a second drug with lercanidipine determined an additional BP decrease of either systolic BP or diastolic BP independently from the type of drug added (P always <0.05). The additional effect of lercanidipine appears widely distributed with no significant differences in the size of BP decrease. From the metabolic point of view, the addition of a second drug did not determine a significant variation in the serum levels of total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol (P always >0.05). Conversely, a significant decrease in fasting plasma glucose and serum levels of triglycerides has been observed in patients where lercanidipine has been combined with an angiotensin-converting enzyme inhibitor or an angiotensin-ll receptor blocker. In conclusion, in our study we observed that lercanidipine-based protocols are well tolerated and efficacious in reducing BP. Moreover, the association of lercanidipine with renin-angiotensin system blockers is also associated with significant improvements in triglycerides and fasting plasma glucose
Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials.
No full textThe oral assumption of lactotripeptides Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP) as nutraceuticals or functional foods is supposed to improve blood pressure (BP) control by angiotensin-converting enzyme-inhibition. However, data derived from clinical trials have reached conflicting conclusions. To perform a meta-analysis of placebo-controlled clinical trials evaluating the anti-hypertensive effect of lactotripeptides assumed as nutraceuticals or functional foods. Trials identified using a defined search strategy in PubMed were included in the meta-analysis, and their pooled effect was estimated with a random effects model, weighting for the inverse of the variance. Heterogeneity, publication bias, subgroup and meta-regression analyses were performed. A total of 18 trials have been identified, the clinical data of which have been clearly reported. Pooled effect of peptides was a reduction of -3.73 mm Hg (95% CI: -6.70, -1.76) for systolic blood pressure (SBP) and 1.97 mm Hg (95% CI: -3.85, -0.64) for diastolic blood pressure (DBP). The effect was more evident in Asian patients (SBP = -6.93 mm Hg (95% CI: -10.95, -2.94); DBP=-3.98 mm Hg(95% CI: -5.38, -2.44)) than in Caucasian ones (SBP=-1.17 mm Hg (95% CI: -2.82, 0.72); DBP = -0.52 mm Hg (95% CI: -1.39, 0.13)), and apparently not related to age, baseline BP values, dose of lactotripeptides assumed or length of the treatment. VPP and IPP lactotripeptides assumed as functional foods may significantly reduce SBP particularly in Asian subjects. The relevance of this findings in other ethnicities or associated with different dietary pattern should to be further investigated
Risk perception and quality of life in children with familial hyperlipidemias and their parents before and after life-style counseling
No full textAntihypertensive efficacy of lactopeptides assumed as functional foods: a meta-analysis of current available clinical trials.
No full textEvaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid lowering propeties: a randomized clinical trial.
No full textAumentare i tassi di risposta al trattamento antiipertensivo: la terapia combinata a dose fissa lercanidipina/enalapril.
No full textAlthough many efforts paid to prevention and treatment of the hypertension, mortality and morbidity hypertension-related is still unacceptably high. This is largely due to the difficulty in mantaining the blood pressure values strictly below the goal recommended by guidelines. As confirmed by recent intervention trials, more than half of hypertensive patients treated with a single drug regime not adeguately controls its blood pressure. On this base, current guidelines have recommended the use of combination therapy as first-line treatment in high or very high risk patients or when blood pressure is above the goal of 20/10 mmHg (>160/100 mmHg). In these patients blocking two or more blood pressure regulatory systems provides a more effectve reduction in blood pressure with a parallell reduction of cardiovascular events. Calcium Channel Blockers (CCBs) and Angiotensin Converting Enzyme (ACE) inhibitors (ACE-I) administered in combination can complemement each other in lowering blood pressure. Recently a fixed-dose combinations of lercanidipine (10 mg) plus enalapril (20 mg) has been approved in some E.C. countries: here we review both the rationale and the available clinical data for the use of this combination in hypertensive patients
Long-term efficacy and safety of a combined nutraceutical added to therapeutic lifestyle in overweight and normoweight dyslipidaemic subjects: a controlled trial
No full textBlood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice
Full text linkThe aim of this study is to assess the blood pressure (BP) and metabolic effects of lercanidipine when combined with other classes of first-line antihypertensive drugs in day-to-day clinical practice. For this study, we consecutively enrolled 162 patients with uncomplicated primary hypertension, who are partial responders to the treatment with lercanidipine over a period of 24 months. Patients were then allocated to the combination of lercanidipine (10–20 mg/day) with β-blockers, diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-II receptor blockers according to compelling indications (if any) and/or suggestions of European Society of Hypertension–European Society of Cardiology (ESH–ESC) guidelines. All the enrolled patients completed the study and no adverse drug reaction was registered during the research period. The association of a second drug with lercanidipine determined an additional BP decrease of either systolic BP or diastolic BP independently from the type of drug added (P always <0.05). The additional effect of lercanidipine appears widely distributed with no significant differences in the size of BP decrease. From the metabolic point of view, the addition of a second drug did not determine a significant variation in the serum levels of total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol (P always >0.05). Conversely, a significant decrease in fasting plasma glucose and serum levels of triglycerides has been observed in patients where lercanidipine has been combined with an angiotensin-converting enzyme inhibitor or an angiotensin-II receptor blocker. In conclusion, in our study we observed that lercanidipine-based protocols are well tolerated and efficacious in reducing BP. Moreover, the association of lercanidipine with renin–angiotensin system blockers is also associated with significant improvements in triglycerides and fasting plasma glucose
- …
